Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

X
Search
Drug Profile

Lazucirnon - Alkahest

Alternative Names: AKST-4290; ALK-429; ALK-4290

Latest Information Update: 28 Aug 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boehringer Ingelheim
  • Developer Alkahest
  • Class Amides; Amines; Anti-inflammatories; Antiparkinsonians; Chlorobenzenes; Eye disorder therapies; Neuroprotectants; Piperidines; Pyridines; Pyrrolidinones; Skin disorder therapies; Small molecules; Toluenes
  • Mechanism of Action Chemokine CCL11 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Age-related macular degeneration; Bullous pemphigoid; Diabetic retinopathy; Parkinson's disease; Wet age-related macular degeneration
  • No development reported Inflammation; Neurodegenerative disorders

Most Recent Events

  • 28 Aug 2024 No recent reports of development identified for phase-I development in Inflammation in USA
  • 02 Aug 2022 Lazucirnon is still in phase I trial for Inflammation in USA (unspecified route) (Alkahest pipeline, August 2022)
  • 09 Feb 2022 Alkahest suspends a Phase-II clinical trial in Diabetic retinopathy in USA, prior to February 2022 (PO) (NCT05038020)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days

Market Movers of 2025 Webinar

This session is built around insights from our in-depth analysis of drug candidates and market shifts expected to shape the pharmaceutical landscape in 2025. We’ll explore two transformative categories (1) Groundbreaking Drug Launches and (2) Patent Expiration & Market Impact. This webinar will also focus on pivotal clinical trials and regulatory milestones, showcasing how data-driven strategies are shaping the development and approval of these market movers.

Register now